Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ondansetron in Schizophrenia
NCT01121042Phase 3Completed
- Start
- Jul 2010
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia, schizoaffective disorder and schizophreniform disorder comparing Ondansetron Arm with Placebo Arm (2 arms). Primary endpoint: Positive and Negative Symptom Scale at 12 weeks. Started Jul 2010; status: completed.
02
Drugs
ondansetron
03
Conditions
schizophreniaschizoaffective disorderschizophreniform disorder
Beyond the preview
Go deeper on NCT01121042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01121042.